(NASDAQ: ARQT) Arcutis Biotherapeutics's forecast annual revenue growth rate of 34.62% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.08%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.39%.
Arcutis Biotherapeutics's revenue in 2025 is $212,819,000.On average, 3 Wall Street analysts forecast ARQT's revenue for 2025 to be $36,846,921,713, with the lowest ARQT revenue forecast at $34,818,823,580, and the highest ARQT revenue forecast at $38,423,841,319. On average, 3 Wall Street analysts forecast ARQT's revenue for 2026 to be $48,720,247,835, with the lowest ARQT revenue forecast at $47,680,689,600, and the highest ARQT revenue forecast at $49,742,879,425.
In 2027, ARQT is forecast to generate $62,143,792,378 in revenue, with the lowest revenue forecast at $53,938,780,110 and the highest revenue forecast at $73,194,626,605.